TrialBritish journal of clinical pharmacology2026

First-in-human, phase I, randomized, safety, pharmacokinetic, food-effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC-1801.

Chris Brearley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.